Management Team

Mr. Commissiong serves as Chief Executive Officer and a member of the Board of Directors of Todos Medical. He has over ten years of experience in therapeutic and diagnostic development, including all aspects of product licensing, research collaborations, and go-to-market strategies. He is the former CEO and co-founder of Amarantus Bioscience, a company that developed LymPro, an Alzheimer’s diagnostic currently being advanced by Todos Medical.

Mr. Commissiong has raised over $70 million in research capital to forward numerous scientific development programs, including those currently underway at Todos. He is a former professional football player for the Calgary Stampeders of the Canadian Football League who received a Bachelor of Science degree in Management Science and Engineering with a focus in Financial Decisions from Stanford University.

Prior to joining Todos Medical, Dr. Trzepacz was the Chief Medical Officer at Neurotrope from June 2016 to September 2016, and has served as a member of Amarantus' Alzheimer's disease Diagnostics Scientific Advisory Board since 2015. Prior to Neurotrope, Dr. Trzepacz was at Eli Lilly and Company for over 15 years where she completed her tenure as Senior Medical Fellow in Neurosciences drug development. She served on the global drug development team for Amyvid, the PET radiotracer indicated for estimation of beta-amyloid plaque density in brains of cognitively impaired persons suspected of having Alzheimer's disease. Prior to that, she led the Phase 2 medical team investigating mibampator, a novel AMPA receptor potentiator, for agitation and aggression in Alzheimer's disease patients. As Senior Medical Fellow on the global Strattera team for over three years, Dr. Trzepacz was the medical lead for registration and regulatory related issues for its ADHD indications for both adult and pediatric populations, including design of new Phase 3 registration trials and collaborations with the European and Japanese Lilly teams. As Senior Medical Director of U.S. Neurosciences, she was responsible for a large medical team of physicians and other scientists, including for the design and execution of many Phase 4 double-blind, randomized placebo-controlled clinical trials over a five-year period. Some of those trials were used to support registration work in addition to answering key patient-relevant questions for practicing physicians. Importantly, the products her team supported included Prozac, Zyprexa, Cymbalta, and Strattera and their multiple indications, line extensions, and formulations.

Dr. Trzepacz is a geriatric psychiatrist and neuropsychiatrist. She is currently Volunteer Clinical Professor of Psychiatry at Indiana University School of Medicine where she has served since 2004. In the past Dr. Trzepacz was Associate Professor of Psychiatry and Neurology at the University of Pittsburgh School of Medicine and Professor of Psychiatry and Neurology at the University of Mississippi Medical School, where she directed clinical services and participated in NIH-funded research. She served as President of the American Neuropsychiatric Association from 2009 to 2011, and of the Academy of Psychosomatic Medicine in 2004-2005. Dr. Trzepacz serves on four journal editorial boards, most recently joining "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring." Dr. Trzepacz earned her B.A. at Wellesley College and M.D. at Geisel School of Medicine at Dartmouth College. After a year of Internal Medicine residency, she completed a Psychiatry residency and Consultation-Liaison Psychiatry Fellowship at Dartmouth.

Mr. Hirsch has over 25 years of experience with a demonstrated history of working with public companies. Mr. Hirsch has management and business development expertise to go along with a strong background in investor relations.

Mr. Gross, MBA is the Vice President of Sales Operations at Todos. Mr. Gross was previously a Managing Director and Co-Founder at WellNova. Prior to that, he was the Chief Operating Officer at Solace Life Sciences where he managed B2B and B2C sales. Priorto Solace, Mr. Gross was a co-founder and Managing Director at Focused Evolution, Inc. Mr. Gross completed his bachelor’s degree in Chemical and Engineering at Western Michigan University and completed his MBA at the University of Delaware.

Dr. Brownell has diversified experience in the biopharmaceutical arena where she has played key roles in discovery, development, opportunity assessment, and Executive Leadership to drive innovation. She has deep experience in discovery research and development through her history at Bayer Healthcare and venture-backed startups, with a focus on rare/orphan diseases, and the bench-to-clinic transition. She earned her BS in Biology from Allegheny College and MS, MPhil and PhD in Biology from Yale University.

Mr. Andrew Blumenthal, RN and international lecturer, comes to Todos with over 20 years in the healthcare industry. Mr. Blumenthal is a seasoned health care professional with an extensive and eclectic background in project financing, technology development and implementation. Prior to joining Todos Medical, Mr. Blumenthal served in executive management positions, including head of health and medical projects at DDU Advisory Service, President of business development for Cross River Medical, partner at Goodlight Capital Group Latin America and managing director of Frontier Medical Ventures USA & Taiwan.

Halperin Ilanit, CPA (Halperin) has over 21 years of experience in one of the six largest accounting firms in Israel, of which the last 11 years she was a partner. Over the years, Halperin has accompanied public and private companies in Israel and abroad in diverse sectors such as: industrial companies, real estate companies, technology companies, tourism companies and more. Halperin has extensive experience in auditing and preparing financial statements according to Israeli, International (IFRS) and US GAAP standards.

Dr. Joseph Wee was appointed managing director of our Singapore operations in July 2016. Dr. Wee has over 45 years of experience as productivity and business management consultant to SMEs, MNCs, Government Linked Companies and Government Agencies. Dr. Wee has held senior management and directorship positions in over 20 companies, including 3 publicly listed companies. Dr. Wee has also served as a member of Advisory Committees appointed by Government Agencies.